ILMN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Illumina Inc (ILMN) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company's strong financial performance, positive news catalysts, and favorable technical indicators support this conclusion. Despite some insider selling and mixed analyst ratings, the long-term growth prospects and recent developments in genomic discovery and diagnostics make it a solid investment opportunity.
The stock shows bullish moving averages (SMA_5 > SMA_20 > SMA_200), with the MACD histogram above 0 and positively contracting, indicating a bullish trend. RSI is neutral at 54.134, suggesting no overbought or oversold conditions. The stock is trading above the pivot level of 125.67, with resistance at 132.913 and support at 118.427.
Illumina's collaboration with Florida State University to improve rare disease diagnostics.
Launch of TruPath Genome with 98% gene phasing, enhancing precision medicine.
Expansion of genomic datasets through partnerships, boosting drug discovery potential.
Strong Q4 financial performance with 4.98% revenue growth and 84.75% EPS growth YoY.
Insider selling has increased significantly (287.98%) in the last month.
Mixed analyst ratings with some price target reductions, such as JPMorgan lowering the target to $
Gross margin dropped slightly (-0.68% YoY).
In Q4 2025, Illumina reported a revenue increase of 4.98% YoY to $1.159 billion, net income growth of 78.61% YoY to $334 million, and EPS growth of 84.75% YoY to 2.18. However, gross margin dropped slightly to 65.49%.
Analyst ratings are mixed. Some firms, like Piper Sandler and JPMorgan, have lowered price targets, while others, like Guggenheim and Evercore ISI, maintain positive outlooks with higher price targets. The consensus indicates cautious optimism, with price targets ranging from $120 to $170.
